Insmed, Inc.(INSM)

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership.

INSM iron condor setups INSM expected move INSM IV rank history INSM Fibonacci levels INSM insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

INSM $117.33 —
Snapshot
$117.33
52-Week Range
$90.39 – $212.75
YTD
-33.76%
IV Rank (30D)
21.18
Straddle Price
$10.00
P/C Vol Ratio
1.30
Market Cap
$26.5B
Fair Value
MODEL: LONG

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)4.96%
Beta vs SPY0.86
Cost of Equity (CAPM)9.26% (VRP-adj)
WACC9.18%
Volatility Risk Premium+13.7pp (IV − HV30)
Effective Tax Rate21.0%
Rev. Growth (YoY, DCF input)+30.0%
DCF Horizon10 years explicit + fade
Forward Tilt (NTM/TTM)×1.10 (applied to P/E, EV/EBITDA, P/S)
Free Cash Flow (TTM)$-0.8B
Return on Equity (TTM)-115.5%
Book / Price3.0%
Gross Margin (TTM)83.5%
FCF Margin (TTM)-71.0%
Debt / Equity0.74
Quality Score2/6 — normal (10y DCF)
SMA 50$119.03 (Market Anchor value)
SMA 20 / Bollinger Mid$123.34
Bollinger Width / SMA208.6% (drives anchor stability)
Net Debt$0.0B
Market Cap$26B
Peers used for multiples: ALNY, AMGN, GH, GILD, LLY, NTRA, REGN, VRTX
Model Conviction
46%
20-Day Fair Value
≈ by Oct 26, 2026
$122.84
α +4.7% rank 29%
40-Day Fair Value
≈ by Nov 24, 2026
$132.29
α +12.8% rank 41%
60-Day Fair Value
≈ by Dec 23, 2026
$123.65
α +5.4% rank 44%
MethodImplied PriceWeightDetail
DCF n/a 0%
DDM (Gordon) n/a 0%
Peer P/E n/a 0% median 29.7× · 5 peers
Peer EV/EBITDA n/a 0% median 25.0× · 6 peers
Peer P/B $67.45 11% median 18.8× · 7 peers
Peer P/S $51.24 11% median 8.6× · 8 peers
Market Anchor (SMA50) $119.03 55% stability 100% (BB-width)
Options Expected (B-L 30d) $120.74 23% 17 strikes · skew +0.73
As of 2026-09-25 · updated
Info
Industry (SIC)
PHARMACEUTICAL PREPARATIONS (2834)
Exchange
XNAS
Market Cap
$26.5B

Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, prote…

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart
Seasonality
MonthAvg ReturnYears of Data
Jan +4.52% 23
Feb +6.65% 23
Mar -4.61% 23
Apr +4.95% 23
May +1.26% 23
Jun +2.22% 23
Jul +1.98% 23
Aug -2.72% 23
Sep +9.66% 24
Oct -0.91% 23
Nov +8.73% 23
Dec -1.22% 23
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $123.13
SMA 50: $119.22
SMA 200: $135.12
Current: $117.30
EMA 12: $121.41
EMA 26: $121.89
MACD: -0.4862 | Signal: -1.0695
BULLISH
ADX (14): 17.10
RANGE
+DI: 15.28
−DI: 26.03

Momentum Oscillators

RSI (14): 43.28
NEUTRAL
Stoch %K: 18.33
Stoch %D: 19.20
Williams %R: -90.47

Volume & Volatility

BB Upper: $130.17
BB Lower: $116.10
NEUTRAL
OBV: 57,889,350
Vol SMA 20: 2,094,638
Vol ROC: 9.39%
ATR: $5.08
True Range: $7.03
HV 20: 39.2%
HV 30: 37.6%
HV 60: 69.9%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-09-26T00:00:00 – 2026-09-24T00:00:00
AI Analysis

LLM Stock Analysis Report

Executive Summary

Overall Assessment: NEUTRAL (Confidence Level: 6/10)

Key Drivers: Recent news sentiment has been mixed, with positive developments in the interstitial lung disease market countered by negative headlines related to the Nasdaq-100 Index. The technical picture is neutral, with a strong trend regime but no clear breakout or breakdown signals.

Primary Risks: Earnings miss or negative guidance, regulatory issues affecting the pharmaceutical industry, and potential volatility spikes driven by changes in interest rates or macroeconomic trends.

Investment Thesis: INSM has potential for long-term growth due to its presence in the interstitial lung disease market. However, short-term volatility and mixed news sentiment create uncertainty around the stock's immediate direction.

Recent News Sentiment Impact: The recent negative headlines have weighed on the stock price, but the positive developments in the interstitial lung disease market could lead to a bounce if earnings are met or exceeded.

Technical Analysis

Trend Direction:

  • Short-term (1-4 weeks): Neutral
  • Medium-term (1-3 months): Uptrend
  • Long-term (3-12 months): Bullish

Support/Resistance Levels: The stock is currently trading near its lower Bollinger Band, with potential support at $92.46. Resistance lies at the upper band ($114.57).

Momentum Signals:

  • RSI interpretation: Neutral (38.39)
  • MACD signal: Bearish (-7.61 / Signal: 0.37 / Histogram: -7.97)
  • Bollinger Bands position: Mean reversion

News & Sentiment Analysis

Recent Headlines Summary: The recent news headlines have been mixed, with negative sentiment dominating the past few weeks.

Sentiment Assessment: Neutral (2/3 positive, 1/3 negative)

Catalyst Identification: Earnings, product launches, and regulatory changes could drive future movements.

Market Narrative: The market is currently pricing in a $13.60 move by expiration, indicating potential volatility ahead.

Risk & Volatility Assessment

Beta Interpretation: INSM has a relatively low beta of 0.66 compared to the SPY (S&P 500), indicating lower risk and greater stability.

Volatility Regime: The stock is currently experiencing moderate volatility, with an IV rank of 43.8% and a historical volatility of 78.9%.

Options Market Signals:

  • IV Premium vs HV30: -20.0% (positive = implied richer than realized)
  • Put/Call Volume Ratio: 1.29 (Neutral sentiment)

Market Context & Positioning

Sector Performance: INSM is performing relatively well within the pharmaceutical sector.

Institutional Activity: Institutional interest is moderate, with a volume flow of 384 calls vs 495 puts and open interest of 3,409 calls vs 3,413 puts.

Correlation Analysis: The stock has a low correlation coefficient of 0.16 compared to the SPY (S&P 500), indicating greater independence from market trends.

Relative Valuation: INSM is positioned within its trading range, with potential support at $92.46 and resistance at $114.57.

Key Levels & Action Items

Critical Price Levels:

  • Support: $92.46
  • Resistance: $114.57

Breakout/Breakdown Levels: A breakout above the upper Bollinger Band could signal a bullish trend, while a breakdown below the lower band could indicate a bearish trend.

Time-Sensitive Catalysts: Earnings and product launches could drive future movements.

Risk Management: Stop-loss levels should be set at $85.00 (1 standard deviation below current price), and position sizing considerations should prioritize risk management.

Please note that this analysis is based on the provided data, but it does not constitute buy/sell advice.

Generated
Earnings History
4 of 7 under expected move
Avg Expected Move
10.83%
Avg Actual Move
13.03%
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2024-10-31 Pre-Market 9.32% 4.26% 0.46x Within
2025-05-08 Pre-Market 9.78% 3.19% 0.33x Within
2025-08-07 Pre-Market 10.83% 1.19% 0.11x Within
2025-10-30 Pre-Market 10.99% 16.81% 1.53x Exceeded
2026-02-19 Pre-Market 7.65% 4.38% 0.57x Within
2026-05-07 Pre-Market 12.40% 23.41% 1.89x Exceeded
2026-08-06 Pre-Market 14.85% 37.98% 2.56x Exceeded
Options Activity
IV Rank (30D)
21.18
IV Rank (7D)
21.18
Avg IV
59.1%
Straddle (30D)
$10.00
Straddle (7D)
$10.00
P/C Volume
1.30
Spread Scanner GPU
Full Algorithm Docs ↗

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score (GPU scanner)

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Enter a ticker to scan for optimal spread opportunities.

Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.

Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d —
— pts EXTREME
ATM — / Wing —
30 DTE / 10d —
— pts EXTREME
ATM — / Wing —

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Enter a ticker to render the implied volatility surface.

Volatility Smile

Enter a ticker to render the implied volatility smile.

IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
Beta (1Y vs SPY)
0.53
Correlation (SPY)
11.1%
R²
0.01
Ann. Volatility
62.5%
SPY Volatility
13.0%

Low volatility - stock moves less than market

Beta & Alpha Over Time
Institutional Ownership (13F)
Latest filings — 2026-06-30
Diluted shares outstanding: 210,898,250 (as of 2026-06-30)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

680 filers243,071,346 shares$26.65B value115.26% of float
# Filer Shares Value % of Total % of Float Period
1 VANGUARD GROUP INC Custodian 21,076,344 $3.67B 13.77% 9.99% 2025-12-31
2 FMR LLC Custodian 16,143,583 $1.72B 6.46% 7.65% 2026-06-30
3 BlackRock, Inc. Custodian 15,807,984 $1.69B 6.32% 7.50% 2026-06-30
4 VANGUARD PORTFOLIO MANAGEMENT LLC 10,407,962 $1.11B 4.16% 4.94% 2026-06-30
5 JPMORGAN CHASE & CO Custodian 10,428,170 $1.09B 4.10% 4.94% 2026-06-30
6 VANGUARD CAPITAL MANAGEMENT LLC 9,790,865 $1.04B 3.92% 4.64% 2026-06-30
7 BAKER BROS. ADVISORS LP 8,796,111 $937.84M 3.52% 4.17% 2026-06-30
8 Capital International Investors 8,238,124 $878.34M 3.30% 3.91% 2026-06-30
9 Invesco Ltd. 4,523,921 $739.75M 2.78% 2.15% 2026-03-31
10 Darwin Global Management, Ltd. 6,431,163 $673.60M 2.53% 3.05% 2026-06-30
11 Orbis Allan Gray Ltd 6,076,487 $647.88M 2.43% 2.88% 2026-06-30
12 STATE STREET CORP (STT, STT-PG) 6,052,174 $645.28M 2.42% 2.87% 2026-06-30
13 D. E. Shaw & Co., Inc. Custodian 5,877,959 $626.71M 2.35% 2.79% 2026-06-30
14 Artisan Partners Limited Partnership 5,441,718 $580.20M 2.18% 2.58% 2026-06-30
15 RTW INVESTMENTS, LP 4,842,880 $516.35M 1.94% 2.30% 2026-06-30
16 GEODE CAPITAL MANAGEMENT, LLC Custodian 4,220,155 $448.76M 1.68% 2.00% 2026-06-30
17 NORGES BANK 3,377,641 $360.12M 1.35% 1.60% 2026-06-30
18 Jupiter Topco LLC 2,605,181 $277.78M 1.04% 1.24% 2026-06-30
19 UBS Group AG Custodian 2,584,446 $275.55M 1.03% 1.23% 2026-06-30
20 CITADEL ADVISORS LLC Custodian 2,556,973 $272.62M 1.02% 1.21% 2026-06-30
21 FRANKLIN RESOURCES INC Custodian 2,273,222 $242.37M 0.91% 1.08% 2026-06-30
22 MAVERICK CAPITAL LTD 2,150,762 $229.31M 0.86% 1.02% 2026-06-30
23 MILLENNIUM MANAGEMENT LLC Custodian 2,048,005 $218.36M 0.82% 0.97% 2026-06-30
24 Qube Research & Technologies Ltd 1,682,334 $179.37M 0.67% 0.80% 2026-06-30
25 WESTFIELD CAPITAL MANAGEMENT CO LP 1,629,561 $173.74M 0.65% 0.77% 2026-06-30
36 filers$474.83M notional
# Filer Notional Value % of Total Period
1 MILLENNIUM MANAGEMENT LLC Custodian $92.12M 19.40% 2026-06-30
2 SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian $76.30M 16.07% 2026-06-30
3 Caption Management, LLC $67.17M 14.15% 2026-06-30
4 JANE STREET GROUP, LLC Custodian $48.16M 10.14% 2026-06-30
5 JPMORGAN CHASE & CO Custodian $47.66M 10.04% 2026-06-30
6 CITADEL ADVISORS LLC Custodian $38.08M 8.02% 2026-06-30
7 TUDOR INVESTMENT CORP ET AL $33.08M 6.97% 2026-06-30
8 Eversept Partners, LP $10.30M 2.17% 2026-06-30
9 GOLDMAN SACHS GROUP INC Custodian $8.93M 1.88% 2026-06-30
10 IMC-Chicago, LLC Custodian $7.11M 1.50% 2026-06-30
11 GROUP ONE TRADING LLC Custodian $6.39M 1.34% 2026-06-30
12 WOLVERINE TRADING, LLC Custodian $6.32M 1.33% 2025-09-30
13 Stonepine Capital Management, LLC $5.60M 1.18% 2026-06-30
14 SIMPLEX TRADING, LLC Custodian $4.80M 1.01% 2026-06-30
15 PEAK6 LLC $3.73M 0.79% 2026-06-30
16 Squarepoint Ops LLC $3.61M 0.76% 2026-06-30
17 CAPITAL FUND MANAGEMENT S.A. $2.31M 0.49% 2026-06-30
18 BALYASNY ASSET MANAGEMENT L.P. $1.78M 0.38% 2026-06-30
19 D. E. Shaw & Co., Inc. Custodian $1.60M 0.34% 2026-06-30
20 MYDA Advisors LLC $1.60M 0.34% 2026-06-30
21 Tidal Investments LLC $1.25M 0.26% 2026-06-30
22 NOMURA HOLDINGS INC $1.16M 0.24% 2026-06-30
23 BNP PARIBAS FINANCIAL MARKETS Custodian $1.07M 0.22% 2026-06-30
24 Walleye Capital LLC $948.92K 0.20% 2026-06-30
25 Walleye Trading LLC $693.03K 0.15% 2026-06-30
28 filers$419.12M notional
# Filer Notional Value % of Total Period
1 GOLDMAN SACHS GROUP INC Custodian $81.87M 19.53% 2026-06-30
2 Caption Management, LLC $78.97M 18.84% 2026-06-30
3 SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian $76.67M 18.29% 2026-06-30
4 JPMORGAN CHASE & CO Custodian $45.04M 10.75% 2026-06-30
5 JANE STREET GROUP, LLC Custodian $36.98M 8.82% 2026-06-30
6 CITADEL ADVISORS LLC Custodian $29.18M 6.96% 2026-06-30
7 IMC-Chicago, LLC Custodian $15.29M 3.65% 2026-06-30
8 Jefferies Financial Group Inc. $11.24M 2.68% 2026-06-30
9 Parallax Volatility Advisers, L.P. $10.91M 2.60% 2026-06-30
10 WOLVERINE TRADING, LLC Custodian $6.97M 1.66% 2025-09-30
11 GROUP ONE TRADING LLC Custodian $4.98M 1.19% 2026-06-30
12 D. E. Shaw & Co., Inc. Custodian $4.81M 1.15% 2026-06-30
13 683 Capital Management, LLC $3.73M 0.89% 2026-06-30
14 CANTOR FITZGERALD, L. P. $2.67M 0.64% 2026-06-30
15 NOMURA HOLDINGS INC $2.13M 0.51% 2026-06-30
16 MILLENNIUM MANAGEMENT LLC Custodian $1.73M 0.41% 2026-06-30
17 SIMPLEX TRADING, LLC Custodian $1.65M 0.39% 2026-06-30
18 BNP PARIBAS FINANCIAL MARKETS Custodian $1.07M 0.25% 2026-06-30
19 TUDOR INVESTMENT CORP ET AL $842.30K 0.20% 2026-06-30
20 SUMMIT SECURITIES GROUP LLC $533.10K 0.13% 2026-06-30
21 Limestone Investment Advisors LP $533.10K 0.13% 2026-06-30
22 Squarepoint Ops LLC $309.20K 0.07% 2026-06-30
23 TWO SIGMA INVESTMENTS, LP Custodian $266.55K 0.06% 2026-06-30
24 Walleye Capital LLC $245.23K 0.06% 2026-06-30
25 Cubist Systematic Strategies, LLC $216.01K 0.05% 2025-09-30
Insider Activity
Latest: 2026-09-11
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-09-11 David R Brennan Director Sell (S) −25,000 $124.00 -$3.10M EDGAR
2026-08-19 MELVIN MD SHAROKY Director Sell (S) −5,000 $127.53 -$637.6K EDGAR
2026-08-12 Roger Adsett Chief Operating Officer Mixed — $76.86 -$27.06M EDGAR
2026-08-07 Martina M.D. Flammer Chief Medical Officer Mixed — $74.91 -$2.92M EDGAR
2026-08-07 Martina M.D. Flammer Chief Medical Officer Mixed — $74.91 -$2.92M EDGAR
2026-07-24 William Lewis Chair and CEO Mixed — $65.50 -$868.0K EDGAR
2026-07-10 William Lewis Chair and CEO Mixed — $71.17 -$989.2K EDGAR
2026-07-08 Martina M.D. Flammer Chief Medical Officer Mixed — $67.89 -$1.04M EDGAR
2026-06-26 William Lewis Chair and CEO Mixed — $64.13 -$1.68M EDGAR
2026-06-24 Michael Alexander Smith Chief Legal Officer Sell (S) −1,806 $95.82 -$173.1K EDGAR
2026-06-24 Samuele Butera SVP, GM, Global Respiratory Award (A) +7,342 — EDGAR
2026-06-10 William Lewis Chair and CEO Sell (S) −6,515 $94.03 -$612.6K EDGAR
2026-06-05 Martina M.D. Flammer Chief Medical Officer Sell (S) −4,424 $102.90 -$455.2K EDGAR
2026-06-05 William Lewis Chair and CEO Sell (S) −7,605 $102.27 -$777.8K EDGAR
2026-06-05 Michael Alexander Smith Chief Legal Officer Sell (S) −2,159 $102.27 -$220.8K EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
Insider Holdings
38 insiders · @ $117.30
Officers, directors, and 10%+ owners ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 William Lewis Chair and CEO 503,682 $59.08M -$120.22M 94 2026-07-24
2 STEINAR J ENGELSEN Director 320,802 $37.63M $834.3K 24 2021-11-03
3 Roger Adsett Chief Operating Officer 257,624 $30.22M -$62.66M 45 2026-08-12
4 MELVIN MD SHAROKY Director 251,504 $29.50M -$8.27M 53 2026-08-19
5 GEOFFREY ALLAN President, CEO and Chairman 182,668 $21.43M $118.0K 3 2009-04-02
6 Christine A Pellizzari Chief Legal Officer 149,985 $17.59M -$7.54M 22 2021-05-18
7 John Drayton Wise Chief Commercial Officer 140,935 $16.53M -$3.03M 14 2025-02-07
8 David R Brennan Director 99,238 $11.64M -$2.80M 17 2026-09-11
9 DAVID W J MCGIRR Director 97,723 $11.46M -$451.5K 16 2026-02-11
10 Clarissa Desjardins Director 73,337 $8.60M $201.7K 9 2026-05-15
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
Notice of Proposed Sale (Form 144)
Latest: 2026-09-10
Last 30d: 1 filing · $3.1M notice value  ·  Last 90d: 9 filings · $45.3M notice value · 6 unique filers · 67% under 10b5-1 plans

What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.

How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.

10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.

"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. Amendments (Form 144/A) and post-cancellation refilings can inflate this if you sum naively; the rollup above excludes filings with zero stated value.

Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.

Top 90-day filers: Roger Adsett (1, $32.0M) · Martina Flammer (2, $4.8M) · William Lewis (3, $4.6M) · Brennan David R (1, $3.1M) · MELVIN SHAROKY (1, $638K)
Filed Filer Role Shares Notice Value Planned Sale Broker Plan Link
2026-09-10 Brennan David R Director 25,000 $3.10M 2026-09-09 Wells Fargo Clearing Services — EDGAR
2026-08-17 MELVIN SHAROKY Director 5,000 $637.6K 2026-08-17 MERRILL LYNCH — EDGAR
2026-08-10 Roger Adsett Officer 239,850 $31.96M 2026-08-10 Merrill Lynch — EDGAR
2026-08-06 Martina Flammer Officer 27,173 $3.49M 2026-08-06 Merrill Lynch 10b5-1 EDGAR
2026-07-23 William Lewis Officer 10,700 $1.13M 2026-07-23 Merrill Lynch 10b5-1 EDGAR
2026-07-09 William Lewis Officer 10,699 $1.26M 2026-07-09 Merrill Lynch 10b5-1 EDGAR
2026-07-06 Martina Flammer Officer 12,302 $1.35M 2026-07-06 Merrill Lynch 10b5-1 EDGAR
2026-06-25 William Lewis Officer 21,398 $2.21M 2026-06-25 Merrill Lynch 10b5-1 EDGAR
2026-06-22 Michael Smith Officer 1,806 $173.0K 2026-06-22 Merrill Lynch 10b5-1 EDGAR
2026-06-08 William Lewis Officer 6,515 $612.6K 2026-06-08 Merrill Lynch 10b5-1 EDGAR
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed.
Recent SEC Filings
Latest: 2026-05-15
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
Filing Date Accession Link
2026-05-15 0001140361-26-021648 EDGAR
2026-05-07 0001140361-26-019430 EDGAR
2026-04-07 0001140361-26-013659 EDGAR
2026-03-23 0001140361-26-010651 EDGAR
2026-02-19 0001140361-26-006116 EDGAR
2026-01-09 0001140361-26-000778 EDGAR
2025-12-17 0001140361-25-045836 EDGAR
2025-11-18 0001140361-25-042598 EDGAR
2025-10-30 0001140361-25-039789 EDGAR
2025-08-12 0001140361-25-030537 EDGAR
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
Filing Date Accession Link
2026-02-19 0001104506-26-000009 EDGAR
2025-02-20 0001104506-25-000009 EDGAR
2024-02-22 0001104506-24-000008 EDGAR
2023-02-23 0001104506-23-000009 EDGAR
2022-02-17 0001104506-22-000008 EDGAR
2021-02-25 0001104506-21-000005 EDGAR
2020-02-25 0001104506-20-000007 EDGAR
2019-02-22 0001104506-19-000009 EDGAR
2018-02-23 0001104506-18-000002 EDGAR
2017-02-23 0001047469-17-000856 EDGAR
Quarterly report — unaudited financials and MD&A. Filed 40–45 days after each of the first three fiscal quarters.
Filing Date Accession Link
2026-05-07 0001104506-26-000032 EDGAR
2025-10-30 0001104506-25-000053 EDGAR
2025-08-07 0001104506-25-000043 EDGAR
2025-05-08 0001104506-25-000026 EDGAR
2024-10-31 0001104506-24-000033 EDGAR
2024-08-08 0001104506-24-000026 EDGAR
2024-05-09 0001104506-24-000016 EDGAR
2023-10-26 0001104506-23-000025 EDGAR
2023-08-03 0001104506-23-000018 EDGAR
2023-05-04 0001104506-23-000012 EDGAR
ETF Holders
# ETF Provider Weight $ Exposure ETF AUM As Of
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

P/B Ratio34.1
P/S Ratio22.7
EV/EBITDA-31.5
TTM Revenue$1.1B
TTM Net Income$-0.9B
TTM EPS$-4.1
ROE-115.5%
Debt/Equity0.75